Advertisement

Pediatric Drugs

, Volume 16, Issue 2, pp 123–128 | Cite as

Quality of Life in Children and Adolescents with Autism Spectrum Disorders: What Is Known About the Effects of Pharmacotherapy?

  • Wendy N. Moyal
  • Catherine Lord
  • John T. Walkup
Leading Article

Abstract

A diagnosis of autistic spectrum disorder (ASD), now estimated to affect one in 88 children, requires deficits in social communication and interactions, and restricted interests and/or repetitive behaviors. Almost all children with ASD have deficits in adaptive skills, many have intellectual disability, and others have co-occurring psychiatric disorders or symptoms. Thus, this complex disorder has shown to have a substantial impact on patients’ quality of life (QoL) and that of their families. Medication treatment is considered by clinicians and families to address problems with functioning due to psychiatric problems, and, as such, one-third of children and adolescents with ASD take at least one psychotropic medication and many use complementary and alternative medicine. This paper reviews what is known about the benefits and risks of psychotropic medications on the QoL of children with ASD. Although scarce, there are studies of psychiatric medications in autistic patients that include QoL measures, such as the pediatric studies of aripiprazole for irritability and one adult study of oxytocin. The aripiprazole study showed a positive effect on QoL in treated patients, as did the oxytocin study. Several other psychotropic medications are used in the treatment of children with ASD, and although information is available on the risks and benefits of each, we do not have specific data on the QoL impact of these medications. The aripiprazole and oxytocin studies exemplify how researchers can include QoL measures and use this information to guide clinicians. Additionally, we will recommend areas of further study in pharmacotherapy and QoL research in the context of treating children with ASD.

Keywords

Autistic Spectrum Disorder Autism Spectrum Disorder Aripiprazole Repetitive Behavior Autistic Spectrum Disorder Child 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of Interest

Dr. Lord receives royalties from Western Psychological Services. Dr. Walkup has received free medications and matching placebo for NIMH-funded studies involving Lily and Pfizer and is currently authoring papers on NIMH-funded studies for which he received free medication from Abbott. He has consulted to Shire once regarding a research study. Dr. Walkup has received research grants, Speaker Bureau Honoraria and travel support from the Tourette Syndrome Association for talks funded by the Center for Disease Control. He has also received royalties for books on Tourette Syndrome from Oxford and Guilford Press. Dr. Walkup is an unpaid member of the following medical or Scientific Advisory Boards: Tourette Syndrome Association, Anxiety Disorders Association of America, and the Trichotillomania Learning Center. Dr Moyal has no conflicts of interest. No sources of funding were used to assist with the preparation of this review.

References

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed (text rev.). Washington, DC; 2013.Google Scholar
  2. 2.
    Murdoch JD, State MW. Recent developments in the genetics of autism spectrum disorders. Curr Opin Genet Dev 2013 Jun;23(3):310-5Google Scholar
  3. 3.
    Ferrans CE, Zerwic JJ, Wilbur JE, Larson JL. Conceptual model of health-related quality of life. J Nurs Scholarsh. 2005;37(4):336–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84:205–11.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Speith LE, Harris CV. Assessment of health-related quality of life in children and adolescents: an integrative review. J Pediatr Psychol 1996;21(2):175–93.Google Scholar
  6. 6.
    Skevington SM, Lotfy M, O’Connell KA; WHOQOL Group. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13(2):299–310.Google Scholar
  7. 7.
    EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199–208.Google Scholar
  8. 8.
    Tavernor L, Barron E, Rodgers J, McConachie H. Finding out what matters: validity of quality of life measurement in young people with ASD. Child Care Health Dev. 2013 Jul;39(4):592-601Google Scholar
  9. 9.
    Tilford JM, et al. Preference-based health-related Quality of Life outcomes in children with autism spectrum disorders: a comparison of generic instruments. Pharmacoeconomics. 2012;30(8):661–79.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Cottenceau H, et al. Quality of life of adolescents with autism spectrum disorders: comparison to adolescents with diabetes. Eur Child Adolesc Psychiatry. 2012;21(5):289–96.PubMedCrossRefGoogle Scholar
  11. 11.
    Kamio Y, Inada N, Koyama T. A nationwide survey on Quality of Life and associated factors of adults with high-functioning autism spectrum disorders. Autism. 2013 Jan;17(1):15-26Google Scholar
  12. 12.
    Kamp-Becker I, et al. Health-related quality of life in adolescents and young adults with high functioning autistic-spectrum disorder. Psychosoc Med. 2010;31:7.Google Scholar
  13. 13.
    Khanna R, Madhavan SS, Smith MJ, Patrick JH, Tworek C, Becker-Cottrill B. Assessment of health-related QoL among primary caregivers of children with autism spectrum disorders. J Autism Dev Disord. 2011;41(9):1214–27.PubMedCrossRefGoogle Scholar
  14. 14.
    Samuel PS, Rillotta F, Brown I. Review: the development of family quality of life concepts and measures. J Intellect Disabil Res. 2012;56(1):1–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Khanna R, et al. Psychometric properties of the Caregiver Strain Questionnaire (CGSQ) among caregivers of children with autism. Autism. 2012;16(2):179–99. doi: 10.1177/1362361311406143 Epub 2011 Jun 29.PubMedCrossRefGoogle Scholar
  16. 16.
    Allik H, Larsson JO, Smedje H. Health-related quality of life in parents of school-age children with Asperger Syndrome or High-Functioning Autism. Health Qual Life Outcomes. 2006;4(4):1.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Griffith GM, Totsika V, Nash S, Jones RS, Hastings RP. “We are all there silently coping.” The hidden experiences of parents of adults with Asperger syndrome. J Intellect Dev Disabil 2012;37(3):237–47Google Scholar
  18. 18.
    Ahmedani BK, Hock RM. Health care access and treatment for children with co-morbid autism and psychiatric conditions. Soc Psychiatry Psychiatr Epidemiol. 2012;47(11):1807.PubMedCrossRefGoogle Scholar
  19. 19.
    Marcus RN, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Marcus RN, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol. 2011;21(3):229–36.Google Scholar
  21. 21.
    Varni JW, et al. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther. 2012;34(4):980–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Anagnostou E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3(1):16.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Olivie H. The medical care of children with autism. Eur J Pediatr. 2012;171:741–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Buie T, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl. 1):S1–18.PubMedCrossRefGoogle Scholar
  25. 25.
    Miano S, Ferri R. Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr Drugs. 2010;12(2):75–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Malow BA, et al. A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. Pediatrics. 2012;130:S106–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Scahill L, et al. Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. J Am Acad Child Adolesc Psychiatry. 2012;51(2):136–46.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    McDougle CJ, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Hollander E, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61(4):498–503.PubMedCrossRefGoogle Scholar
  30. 30.
    Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Coury DL et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics. 2012;130(Suppl. 2):S69–76.17Google Scholar
  32. 32.
    Williams K et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders. Cochrane Database Syst Rev. 2010;8:CD004677Google Scholar
  33. 33.
    Dolske MC, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17(5):765–74.PubMedGoogle Scholar
  34. 34.
    Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 2005;(4):CD003497Google Scholar
  35. 35.
    James S et al. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2011;(11):CD007992Google Scholar
  36. 36.
    Posey DJ et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004;161:2115–7Google Scholar
  37. 37.
    Sandler RH, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000;15(7):429–35.PubMedCrossRefGoogle Scholar
  38. 38.
    Centers for Disease Control and Prevention. Deaths associated with hypocalcemia from chelation therapy: Texas, Pennsylvania and Oregon, 2003–2005. Morb Mort Wkly Rep. 2006;55:204–7.Google Scholar
  39. 39.
    Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11(2):131–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Whiteley P, et al. Gluten- and casein-free dietary intervention for autism spectrum conditions. Front Hum Neurosci. 2012;6:344. doi: 10.3389/fnhum.2012.00344 Epub 2013 Jan 4.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Institute of Medicine (US) Immunization Safety Review Committee. Immunization safety review: vaccines and autism. Washington, DC: National Academies Press; 2004.Google Scholar
  42. 42.
    Parker SK, Schwartz B, et al. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004;114(3):793–804.PubMedCrossRefGoogle Scholar
  43. 43.
    van Steensel FJA, Bögels SM, Dirksen CD. Anxiety and Quality of Life: clinically anxious children with and without autism spectrum disorders compared. J Clin Child Adol Psych 2012;41:6, 731–8.Google Scholar
  44. 44.
    Sikora DM, Vora P, Coury DL, Rosenberg D. Attention-deficit/hyperactivity disorder symptoms, adaptive functioning, and quality of life in children with autism spectrum disorder. Pediatrics. 2012;130(Suppl. 2):S91–7.PubMedCrossRefGoogle Scholar
  45. 45.
    RUPP Autism Network. Risperidone in children with autism and serious behavioral problems. NEJM. 2002;347:314–21.CrossRefGoogle Scholar
  46. 46.
    Phetrasuwan S, Shandor Miles M. Parenting stress in mothers of children with autism spectrum disorders. J Spec Pediatr Nurs 2009;14(3):157–65Google Scholar
  47. 47.
    Sterzing PR, Shattuck PT, Narendorf SC, Wagner M, Cooper BP. Bullying involvement and autism spectrum disorders: prevalence and correlates of bullying involvement among adolescents with an autism spectrum disorder. Arch Pediatr Adolesc Med. 2012;3:1–7.Google Scholar
  48. 48.
    RUPP Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266–74.CrossRefGoogle Scholar
  49. 49.
    Jaselskis CA, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J ClinPsychopharmacol. 1992;12(5):322–7.Google Scholar
  50. 50.
    Scahill L, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):589–98.PubMedCrossRefGoogle Scholar
  51. 51.
    Arnold LE et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006;45(10):1196–205Google Scholar
  52. 52.
    Posey DJ, et al. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):599–610.PubMedCrossRefGoogle Scholar
  53. 53.
    King BH et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66(6):583–90Google Scholar
  54. 54.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (text rev.). Washington, DC; 2000Google Scholar
  55. 55.
    Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, Tager-Flusberg H, Lainhart JE. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord. 2006;36(7):849–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Wendy N. Moyal
    • 1
  • Catherine Lord
    • 1
    • 2
  • John T. Walkup
    • 1
  1. 1.Department of PsychiatryWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Center for Autism and the Developing BrainWeill Cornell Medical College/NY Presbyterian HospitalWhite PlainsUSA

Personalised recommendations